Gulf International Bank UK Ltd Raises Position in Stryker Co. (SYK)

Share on StockTwits

Gulf International Bank UK Ltd boosted its stake in shares of Stryker Co. (NYSE:SYK) by 0.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,700 shares of the medical technology company’s stock after buying an additional 385 shares during the period. Gulf International Bank UK Ltd’s holdings in Stryker were worth $15,544,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. ERTS Wealth Advisors LLC acquired a new position in Stryker during the 4th quarter worth about $25,000. Northwest Wealth Management LLC lifted its stake in Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 86 shares in the last quarter. Semmax Financial Advisors Inc. acquired a new position in Stryker during the 4th quarter worth about $28,000. Horan Securities Inc. acquired a new position in Stryker during the 4th quarter worth about $30,000. Finally, Truehand Inc acquired a new position in Stryker during the 4th quarter worth about $30,000. 74.61% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Michael Damon Hutchinson sold 15,995 shares of the stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $180.49, for a total value of $2,886,937.55. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $192.40, for a total value of $897,738.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 130,455 shares of company stock worth $24,723,292. Company insiders own 7.20% of the company’s stock.

Several equities analysts recently issued reports on the company. Barclays increased their target price on Stryker from $203.00 to $211.00 and gave the stock an “overweight” rating in a research note on Monday, April 15th. Zacks Investment Research lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday, April 12th. BTIG Research increased their target price on Stryker to $211.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. ValuEngine lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday. Finally, Deutsche Bank assumed coverage on Stryker in a research note on Wednesday, January 2nd. They set a “buy” rating and a $179.00 target price on the stock. Nine analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $192.13.

Shares of NYSE SYK opened at $180.26 on Friday. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.72. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $199.85. The stock has a market cap of $67.26 billion, a price-to-earnings ratio of 24.66, a P/E/G ratio of 2.38 and a beta of 0.88.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The company had revenue of $3.80 billion for the quarter, compared to the consensus estimate of $3.73 billion. On average, research analysts expect that Stryker Co. will post 8.13 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a $0.52 dividend. The ex-dividend date is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.15%. Stryker’s payout ratio is currently 28.45%.

WARNING: “Gulf International Bank UK Ltd Raises Position in Stryker Co. (SYK)” was originally reported by Zolmax and is owned by of Zolmax. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://zolmax.com/investing/gulf-international-bank-uk-ltd-raises-position-in-stryker-co-syk/3049299.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: Market Capitalization – What it Means for Investors

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HCP, Inc.  Given Consensus Rating of “Buy” by Analysts
HCP, Inc. Given Consensus Rating of “Buy” by Analysts
Guaranty Federal Bancshares, Inc.  Given Average Recommendation of “Buy” by Brokerages
Guaranty Federal Bancshares, Inc. Given Average Recommendation of “Buy” by Brokerages
Central Valley Community Bancorp  Expected to Announce Earnings of $0.40 Per Share
Central Valley Community Bancorp Expected to Announce Earnings of $0.40 Per Share
-$1.20 EPS Expected for Catalyst Biosciences Inc  This Quarter
-$1.20 EPS Expected for Catalyst Biosciences Inc This Quarter
Brokerages Set $48.00 Target Price for Lydall, Inc.
Brokerages Set $48.00 Target Price for Lydall, Inc.
First Republic Bank  Earns “Outperform” Rating from Wedbush
First Republic Bank Earns “Outperform” Rating from Wedbush


 
© 2006-2019 Zolmax.